Prognostic significance of blood inflammatory biomarkers NLR, PLR, and LMR in cancer-A protocol for systematic review and meta-analysis

Chellan Kumarasamy, Shanthi Sabarimurugan, Royam Madhav Madurantakam, Kartik Lakhotiya, Suja Samiappan, Siddhratha Baxi, Ramesh Nachimuthu, Kodiveri Muthukaliannan Gothandam, Rama Jayaraj

Research output: Contribution to journalArticleResearchpeer-review

1 Downloads (Pure)

Abstract

Background: The neutrophil-lymphocyte-ratio, platelet-lymphocyte-ratio, and monocyte-lymphocyte-ratio have been explored as a simple, inexpensive, and effective method for cancer prognosis. However, there are no studies that have investigated the comparative utility of these markers, in multiple cancers.

Methods: The preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) guidelines were used to design this meta-analysis protocol. The final study will also be conducted under the PRISMA guidelines for systematic reviews and meta-analyses. The core bibliographic database search will be carried out by 2 reviewers working individually, with each conducting an initial screening based on titles and abstracts. The shortlisted articles will be selected for review and quantitative analysis, based on predefined inclusion and exclusion criteria. Study characteristics, relevant clinicopathological characteristics, and statistical data required for meta-analysis (hazard ratios [HRs] and 95% confidence intervals [CIs]) will be extracted and compiled into a MS Excel datasheet. Meta-analysis will be performed, using a random-effects model, and the results (pooled HR and 95% CI) will be presented in the form of a forest plot. Publication bias will also be assessed by use of Egger bias indicator test and funnel plot symmetry. If statistical data from included studies is insufficient, a qualitative literature review will be pursued. PROSPERO registration: PROSPERO CRD42019121008.

Original languageEnglish
Article numbere14834
Pages (from-to)1-6
Number of pages6
JournalMedicine
Volume98
Issue number24
DOIs
Publication statusPublished - 1 Jun 2019

Fingerprint

Meta-Analysis
Biomarkers
Lymphocytes
Neoplasms
Guidelines
Bibliographic Databases
Confidence Intervals
Publication Bias
Monocytes
Neutrophils
Blood Platelets

Cite this

Kumarasamy, Chellan ; Sabarimurugan, Shanthi ; Madurantakam, Royam Madhav ; Lakhotiya, Kartik ; Samiappan, Suja ; Baxi, Siddhratha ; Nachimuthu, Ramesh ; Gothandam, Kodiveri Muthukaliannan ; Jayaraj, Rama. / Prognostic significance of blood inflammatory biomarkers NLR, PLR, and LMR in cancer-A protocol for systematic review and meta-analysis. In: Medicine. 2019 ; Vol. 98, No. 24. pp. 1-6.
@article{d9074ac367aa439e83e40cfcbdafa20c,
title = "Prognostic significance of blood inflammatory biomarkers NLR, PLR, and LMR in cancer-A protocol for systematic review and meta-analysis",
abstract = "Background: The neutrophil-lymphocyte-ratio, platelet-lymphocyte-ratio, and monocyte-lymphocyte-ratio have been explored as a simple, inexpensive, and effective method for cancer prognosis. However, there are no studies that have investigated the comparative utility of these markers, in multiple cancers. Methods: The preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) guidelines were used to design this meta-analysis protocol. The final study will also be conducted under the PRISMA guidelines for systematic reviews and meta-analyses. The core bibliographic database search will be carried out by 2 reviewers working individually, with each conducting an initial screening based on titles and abstracts. The shortlisted articles will be selected for review and quantitative analysis, based on predefined inclusion and exclusion criteria. Study characteristics, relevant clinicopathological characteristics, and statistical data required for meta-analysis (hazard ratios [HRs] and 95{\%} confidence intervals [CIs]) will be extracted and compiled into a MS Excel datasheet. Meta-analysis will be performed, using a random-effects model, and the results (pooled HR and 95{\%} CI) will be presented in the form of a forest plot. Publication bias will also be assessed by use of Egger bias indicator test and funnel plot symmetry. If statistical data from included studies is insufficient, a qualitative literature review will be pursued. PROSPERO registration: PROSPERO CRD42019121008.",
author = "Chellan Kumarasamy and Shanthi Sabarimurugan and Madurantakam, {Royam Madhav} and Kartik Lakhotiya and Suja Samiappan and Siddhratha Baxi and Ramesh Nachimuthu and Gothandam, {Kodiveri Muthukaliannan} and Rama Jayaraj",
year = "2019",
month = "6",
day = "1",
doi = "10.1097/MD.0000000000014834",
language = "English",
volume = "98",
pages = "1--6",
journal = "Medicine",
issn = "0025-7974",
publisher = "Lippincott Williams & Wilkins",
number = "24",

}

Kumarasamy, C, Sabarimurugan, S, Madurantakam, RM, Lakhotiya, K, Samiappan, S, Baxi, S, Nachimuthu, R, Gothandam, KM & Jayaraj, R 2019, 'Prognostic significance of blood inflammatory biomarkers NLR, PLR, and LMR in cancer-A protocol for systematic review and meta-analysis', Medicine, vol. 98, no. 24, e14834, pp. 1-6. https://doi.org/10.1097/MD.0000000000014834

Prognostic significance of blood inflammatory biomarkers NLR, PLR, and LMR in cancer-A protocol for systematic review and meta-analysis. / Kumarasamy, Chellan; Sabarimurugan, Shanthi; Madurantakam, Royam Madhav; Lakhotiya, Kartik; Samiappan, Suja; Baxi, Siddhratha; Nachimuthu, Ramesh; Gothandam, Kodiveri Muthukaliannan; Jayaraj, Rama.

In: Medicine, Vol. 98, No. 24, e14834, 01.06.2019, p. 1-6.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Prognostic significance of blood inflammatory biomarkers NLR, PLR, and LMR in cancer-A protocol for systematic review and meta-analysis

AU - Kumarasamy, Chellan

AU - Sabarimurugan, Shanthi

AU - Madurantakam, Royam Madhav

AU - Lakhotiya, Kartik

AU - Samiappan, Suja

AU - Baxi, Siddhratha

AU - Nachimuthu, Ramesh

AU - Gothandam, Kodiveri Muthukaliannan

AU - Jayaraj, Rama

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Background: The neutrophil-lymphocyte-ratio, platelet-lymphocyte-ratio, and monocyte-lymphocyte-ratio have been explored as a simple, inexpensive, and effective method for cancer prognosis. However, there are no studies that have investigated the comparative utility of these markers, in multiple cancers. Methods: The preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) guidelines were used to design this meta-analysis protocol. The final study will also be conducted under the PRISMA guidelines for systematic reviews and meta-analyses. The core bibliographic database search will be carried out by 2 reviewers working individually, with each conducting an initial screening based on titles and abstracts. The shortlisted articles will be selected for review and quantitative analysis, based on predefined inclusion and exclusion criteria. Study characteristics, relevant clinicopathological characteristics, and statistical data required for meta-analysis (hazard ratios [HRs] and 95% confidence intervals [CIs]) will be extracted and compiled into a MS Excel datasheet. Meta-analysis will be performed, using a random-effects model, and the results (pooled HR and 95% CI) will be presented in the form of a forest plot. Publication bias will also be assessed by use of Egger bias indicator test and funnel plot symmetry. If statistical data from included studies is insufficient, a qualitative literature review will be pursued. PROSPERO registration: PROSPERO CRD42019121008.

AB - Background: The neutrophil-lymphocyte-ratio, platelet-lymphocyte-ratio, and monocyte-lymphocyte-ratio have been explored as a simple, inexpensive, and effective method for cancer prognosis. However, there are no studies that have investigated the comparative utility of these markers, in multiple cancers. Methods: The preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) guidelines were used to design this meta-analysis protocol. The final study will also be conducted under the PRISMA guidelines for systematic reviews and meta-analyses. The core bibliographic database search will be carried out by 2 reviewers working individually, with each conducting an initial screening based on titles and abstracts. The shortlisted articles will be selected for review and quantitative analysis, based on predefined inclusion and exclusion criteria. Study characteristics, relevant clinicopathological characteristics, and statistical data required for meta-analysis (hazard ratios [HRs] and 95% confidence intervals [CIs]) will be extracted and compiled into a MS Excel datasheet. Meta-analysis will be performed, using a random-effects model, and the results (pooled HR and 95% CI) will be presented in the form of a forest plot. Publication bias will also be assessed by use of Egger bias indicator test and funnel plot symmetry. If statistical data from included studies is insufficient, a qualitative literature review will be pursued. PROSPERO registration: PROSPERO CRD42019121008.

UR - http://www.scopus.com/inward/record.url?scp=85068129186&partnerID=8YFLogxK

U2 - 10.1097/MD.0000000000014834

DO - 10.1097/MD.0000000000014834

M3 - Article

VL - 98

SP - 1

EP - 6

JO - Medicine

JF - Medicine

SN - 0025-7974

IS - 24

M1 - e14834

ER -